PACE - Pacing and Clinical Electrophysiology, cilt.46, sa.1, ss.44-49, 2023 (SCI-Expanded)
© 2022 Wiley Periodicals LLC.Background: Empagliflozin is a new antidiabetic drug with positive effects on glucose regulation and the prevention of cardiovascular diseases (CVD). The effect of empagliflozin on arrhythmias has not been adequately studied. The index of cardio-electrophysiological balance (iCEB) is a popular marker used to predict ventricular arrhythmias. Therefore, in our study, we aimed to examine the effect of empagliflozin on iCEB and iCEBc in patients with type 2 diabetes mellitus (T2DM) without heart failure (HF). Methods: A total of 70 patients were included in the study prospectively. Electrocardiographic and echocardiographic evaluations of all patients were reviewed at baseline and the end of the third month. Results: The median age of the patients was 57 (43–68 IQR), and 30 (42.9%) were male. Tp-e (100 [88–120] vs. 94 [82–105], p =.01), Tp-e/QT (0.27 [0.25–0.33] vs. 0.25 [0.23–0.30], p =.001) were significantly shorter after treatment. iCEB (4.24 [3.8–4.5] vs. 3.92 [3.79–4.42], p =.009) and iCEBc (4.78 [4.25–4.92] vs. 4.48 [4.0–4.71], p =.001) values decreased significantly after treatment compared to baseline. Conclusions: Tp-e, Tp-e/QT, iCEB, and iCEBc values decreased within physiological limits in patients with T2DM without HF. This result may be associated with a reduced risk of potential ventricular arrhythmias.